Xeltis, a medical technology firm specializing in transformative implants, has successfully secured an additional €20.5 million in funding. The round was led by new investor Horizon 3 Healthcare, with significant participation from existing shareholders like the European Innovation Council. This capital is earmarked to accelerate the company's clinical, regulatory, and commercial objectives for its innovative vascular solutions.
Strategic Allocation of New Capital
The newly acquired funds will be strategically deployed to advance Xeltis' key initiatives across multiple fronts. A primary focus is finalizing the ongoing US pivotal trial for its aXess™ vascular access solution and preparing for FDA submission. The capital will also fuel the European commercial rollout of aXess™, which recently saw its first use in Germany.
Beyond the immediate goals for aXess™, the financing will support a significant upscaling of Xeltis' manufacturing capabilities. This expansion is crucial to meet anticipated demand in European and American markets following regulatory approvals. Furthermore, the company will advance its other clinical programs, XABG and XPAD, diversifying its product pipeline.
Investor Confidence and Market Momentum
This latest funding round, which builds upon a €50 million financing secured in 2025, signals strong investor confidence in Xeltis' vision. The participation of new lead investor Horizon 3 Healthcare alongside continued backing from established partners underscores belief in the company's strategy. This financial reinforcement strengthens Xeltis' position as it navigates its next phase of growth.
Matt McNamara, Chief Investment Officer of Horizon 3 Healthcare, highlighted the compelling data from Xeltis as a key factor in their investment. He noted the potential of aXess™ to significantly improve outcomes for hemodialysis patients and praised the company's rapid progress. This sentiment was echoed by existing investors, who pointed to the recent European launch as a major milestone.
Pioneering Vascular Regeneration Technology
At the core of Xeltis' innovation is its proprietary Restorex® platform, representing a paradigm shift in vascular implants. Unlike traditional synthetic replacements, Xeltis' technology enables the patient's body to naturally create its own living and long-lasting vessels. The advanced polymer implant is gradually absorbed by the body, leaving behind new, functional tissue.
The company's flagship product, aXess™, is an implantable blood vessel designed for hemodialysis vascular access, a critical need for patients with kidney failure. By facilitating the creation of a living vessel, aXess™ aims to reduce the need for repeat interventions and address common complications. This approach holds significant potential to improve the quality of life for millions of patients.
Leadership and Vision for the Future
Eliane Schutte, CEO of Xeltis, stated that the fundraising will enable the company to bring its technology to more patients in Europe and the US. She emphasized the dual focus on advancing the aXess™ pivotal trial while continuing the successful commercial rollout. Schutte welcomed the new investor and thanked all partners for their confidence in the company's mission.
The European Innovation Council also praised Xeltis for pioneering a new approach that moves beyond permanent implants. Board Member Hermann Hauser noted that this shift illustrates how transformative technology can open new possibilities for patients. This support reinforces Europe's position as a leader in breakthrough medical innovations turning concepts into clinical reality.
The successful €20.5 million funding round marks a pivotal moment for Xeltis, providing resources to accelerate its expansion into key global markets. With strong investor support and a revolutionary technology platform, the company is well-positioned to transform the landscape of vascular access for hemodialysis. This strategic investment will help bring a much-needed, long-lasting solution to patients worldwide.